MedPage Today  3 hrs ago  Comment 
(MedPage Today) -- A year of treatment with teriparatide failed to repair damage
Benzinga  May 23  Comment 
Barclays initiated coverage of Zymeworks Inc (NYSE: ZYME) with an Overweight rating and price target of $20. The company released first-quarter earnings last week, reporting ($1.13) EPS on the quarter with revenue of $0.23 million. Early-Stage,...
Motley Fool  May 21  Comment 
Looking for top animal-health companies to buy? Check out Zoetis, Merck, and Lilly.
FiercePharma  May 18  Comment 
Investors are champing at the bit for data that will help them determine how Eli Lilly’s candidate abemaciclib stacks up against its in-class rivals—particularly Pfizer’s fast-growing Ibrance—in the efficacy department. But analysts say...
GenEng News  May 12  Comment 
Eli Lilly said it will submit a Biologics License Application (BLA) to the FDA later this year for its monoclonal antibody (mAb) migraine candidate galcanezumab, on the back of positive data from three Phase III studies.  Developed to block...
MarketWatch  May 12  Comment 
Eli Lilly shares gain premarket on positive trial for migraine treatment
Insurance Journal  May 10  Comment 
The American Insurance Association (AIA) announced today that President and CEO Leigh Ann Pusey will be stepping down on June 9, after leading the organization since 2009. Pusey is leaving to join global pharmaceutical firm Eli Lilly and Co. as …
GenEng News  May 8  Comment 
OncoMed is halting clinical development of its anticancer stem cell drug demcizumab (anti-DLL4, OMP-21M18) after a Phase II combination therapy study in front-line nonsquamous, non-small-cell lung cancer (NSCLC) failed to meet its primary...
FiercePharma  May 2  Comment 
Eli Lilly's insulin pricing scrutiny intensifies with newly disclosed state AG probes esagonowsky Tue, 05/02/2017 - 09:26

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki